OHSU IIT: A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer
The purpose of this study is to assess the safety and tolerability of the combination of abemacicilib and niraparib in early-stage hormone receptor-positive breast cancer.
We also want to learn more about how participants' tumors respond to this treatment by performing clinical tests on biopsied tumor tissue.
Hormone Receptor-positive, HER2-negative Breast Cancer
Females 18 years and older
Biopsy proven HR-positive breast cancer
Must be able to undergo biopsy
No prior PARP or CDK 4/6 inhibitor exposure
18 - 101
Healthy Volunteers Needed
Duration of Participation
You will receive the study drugs for up to 16 weeks (112 days) before going to surgery. After surgery, the investigator or study team will continue to watch you for side effects and follow your condition either with follow-up clinic visits or follow-up phone calls for 5 years or until the study has been completed.
Knight Cancer Institute Clinical Trials
OHSU Knight Cancer Institute